Instructions Suprilex tablets 10 mg blister No. 30
Composition
active ingredient: isoxsuprine hydrochloride;
1 tablet contains isoxsuprine hydrochloride 10 mg;
excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silicon dioxide.
Dosage form
Pills.
Main physicochemical properties: round, flat, white tablets, with a score on one side.
Pharmacotherapeutic group
Peripheral vasodilators. Derivatives of 2-amino-1-phenylethanol. ATC code C04A A01.
Pharmacological properties
Pharmacodynamics
Isoxsuprine is a peripheral vasodilator, beta-adrenergic receptor agonist. Due to its stimulating effect on beta-adrenergic receptors, isoxsuprine reduces the tone of smooth muscles of blood vessels, eliminates their spasm, improves peripheral and cerebral blood circulation and, accordingly, blood supply to tissues. It exhibits a positive inotropic and chronotropic cardiac effect, as well as a tocolytic effect. In in vitro and in vivo studies, isoxsuprine suppressed spontaneous and oxytocin-induced uterine activity during labor.
Isoxsuprine also has a slight bronchodilator effect. In large doses, it inhibits platelet aggregation and reduces blood viscosity.
Pharmacokinetics
Isoxsuprine is rapidly absorbed from the gastrointestinal tract. It is metabolized by partial conjugation in the liver. With oral administration, maximum plasma concentration is reached within about 1 hour. The half-life is about 1.25 hours. It is excreted mainly in the urine, to a small extent in the feces.
Indication
Peripheral circulatory disorders, including obliterating endarteritis, obliterating atherosclerosis of the arteries of the extremities, diabetic angiopathy, Raynaud's disease and syndrome. Chronic cerebral vascular insufficiency in cerebral atherosclerosis. Atherosclerosis of the retinal arteries.
Contraindication
Hypersensitivity to the active substance or to any other component of the drug. Bleeding and hemorrhage, including a history. Angina pectoris. Arterial hypotension. The use of the drug immediately after childbirth is contraindicated.
Interaction with other medicinal products and other types of interactions
There are no data on the negative interaction of isoxuprine with other drugs. It is possible to enhance the vasodilator effect when used simultaneously with vasodilators used in cardiology.
Application features
Do not exceed the dose and duration of treatment prescribed by your doctor. If you experience any unusual reactions during use of the drug, you should consult a doctor.
The drug should be prescribed with caution in the presence of tachycardia, hot flashes, blood clotting disorders, glaucoma, and in the acute phase of myocardial infarction and stroke.
During treatment with the drug, elderly patients should be careful when getting out of bed and avoid sudden changes in body position in order to prevent orthostatic hypotension.
The effect of the drug may be reduced in patients who smoke.
Do not drink alcoholic beverages during treatment with Suprilex®.
The development of pulmonary edema in the mother and tachycardia in the fetus has been recorded when isoxuprine is administered intravenously during preterm labor.
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug may cause drowsiness or dizziness. In this case, you should avoid driving vehicles and working with complex mechanisms.
Use during pregnancy or breastfeeding
Pregnancy.
Isoxsuprine is contraindicated in pregnant women.
Breastfeeding period.
There is no data on the safety of isoxsuprine during breastfeeding, so the use of the drug should be avoided during this period.
Method of administration and doses
The drug should be taken orally at a dose of 10-20 mg 3-4 times a day after meals. The course of treatment is 2-3 months.
Children
There is no data on the safety of isoxuprine in children, so the drug should not be used in children under 18 years of age.
Overdose
Symptoms: tachycardia, palpitations, chest pain, low blood pressure (collapse), dizziness, weakness, loss of consciousness, nausea, vomiting.
Treatment: symptomatic.
Adverse reactions
Cardiovascular system: tachycardia, palpitations, arterial hypotension, orthostatic hypotension, chest pain.
From the nervous system: dizziness, loss of consciousness.
On the part of the digestive system: dyspeptic disorders, nausea, vomiting.
Skin and subcutaneous tissue disorders: skin rashes.
General condition and disorders related to the method of administration of the drug: weakness, feeling of hot flashes.
Immune system disorders: hypersensitivity reactions.
Respiratory system: shortness of breath.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 tablets in blisters; 3 blisters in a cardboard box.
Vacation category
According to the recipe.
Producer
KUSUM HEALTHCARE PVT LTD/ KUSUM HEALTHCARE PVT LTD.
Location of the manufacturer and its business address
SP-289 (A), RIICO Industrial area, Chopanki, Bhiwadi, Dist. Alwar (Rajasthan), India.
